Disseminated Coccidioidomycosis in Immunocompetent Hosts: Opportunities for Increased Recognition and Timely Diagnosis
Clinical Chemistry · 2026
DOI: 10.1093/clinchem/hvaf187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2026. Verfasst von Anna C H Hoge und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ, United States. Hauptthemen laut MEDLINE: Coccidioidomycosis, Immunocompetence. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
While most pulmonary infections with Coccidioides spp. are self-limited, a subset of patients is at higher risk for severe disease and extrapulmonary dissemination, including individuals with certain ethnic backgrounds. Disseminated disease can involve soft tissues, bones, and the central nervous system with high morbidity and mortality in the absence of antifungal treatment. Diagnosis of coccidioidomycosis can be challenged by the availability of specimens for culture or histopathology, confusion with, or lack of availability of various antibody tests and overall lack of consideration of Coccidioides spp. as the etiology of disease, especially in immunocompetent hosts.
Methods
We set out to characterize cases of disseminated coccidioidomycosis at our institution over a 7-year period, solely in immunocompetent hosts, to highlight diagnostic delays and determine which, if any, primary screening test might be the most useful.
Results
A total of 40 cases met our inclusion criteria, and 100% of these cases had positive immunoglobulin G antibodies on a US FDA-cleared Coccidioides spp. enzyme immunoassay. Nearly all of the cases (87%) had a delay in diagnosis and associated worsening of disease (71%). Locations of initial presentations that led to delayed recognition included primary care settings (56%), emergency departments (33%), and urgent care centers (11%), all in the region of Coccidioides spp. endemicity.
Conclusions
These findings highlight the need for interventions to increase awareness of the risk factors for, the symptoms of, and the appropriate testing options to diagnose disseminated coccidioidomycosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ, United States.
ORCID-Profile: Thomas E Grys, Erin H Graf
Zitieren
APA
Hoge, A. C. H., Grys, T. E., & Graf, E. H. (2026). Disseminated Coccidioidomycosis in Immunocompetent Hosts: Opportunities for Increased Recognition and Timely Diagnosis. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvaf187
Vancouver
Hoge ACH, Grys TE, Graf EH. Disseminated Coccidioidomycosis in Immunocompetent Hosts: Opportunities for Increased Recognition and Timely Diagnosis. Clinical Chemistry. 2026. doi:10.1093/clinchem/hvaf187
BibTeX
@article{Hoge2026,
author = {Hoge, Anna C H and Grys, Thomas E and Graf, Erin H},
title = {Disseminated Coccidioidomycosis in Immunocompetent Hosts: Opportunities for Increased Recognition and Timely Diagnosis},
journal = {Clinical Chemistry},
year = {2026},
doi = {10.1093/clinchem/hvaf187}
}
EUVIMED